Iron deficiency commonly affects patients with chronic kidney disease and has an important
burden in disease trajectory and quality of life; nonetheless current guidelines do not …

Background Concerns exist regarding the pro-oxidant and inflammatory potential of
intravenous (IV) iron due to labile plasma iron (LPI) generation. This IRON-CKD trial …

Chronic kidney disease (CKD) represents a state of oxidative stress imbalance, which is
potentially amplified by iron deficiency. Intravenous iron is considered safe and efficacious …

Iron is an essential nutrient, but carries potential risks. Iron therapy not only affects the
functions of leukocytes, endothelial cells, and cytokine production, but also causes oxidative …

Intravenous iron supplementation is a recognized therapy for anemia in chronic
hemodialysis patients, especially in those treated with erythropoietin. The vast majority of …

Although judicious use of intravenous iron preparations is an indispensable part of anemia
treatment in hemodialysis patients, their excessive and indiscriminate use can have …

Intravenous (IV) iron supplementation is widely used to support erythropoeisis in
hemodialysis patients. IV iron products are associated with oxidative stress that has been …

Intravenous iron increases labile serum iron but does not impair forearm blood flow reactivity
in dialysis patients. Background There are concerns about adverse vascular effects of …

Background: Iron deficiency (ID) is common in patients with chronic kidney disease (CKD)
due to an inadequate dietary intake of iron, poor absorption from the gut and increased iron …

Background Iron deficiency (ID) is common in patients with chronic kidney disease (CKD).
Intravenous (IV) iron in heart failure leads to improvement in exercise capacity and …